Pure Global
NCT06285240

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MK-1167 Administered to Patients With Alzheimer's Disease Receiving Stable Donepezil Treatment
Merck Sharp & Dohme LLC·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Alzheimer's Disease
Drug/Device/Intervention
MK-1167
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Merck Sharp & Dohme LLC
Timeline & enrollment
Phase
Phase 1
Start date
Mar 15, 2024
End date
Jul 25, 2024
Enrollment
16 participants
Primary outcome

Number of participants experiencing an Adverse Event (AE),Number of participants discontinuing study treatment due to an AE

Summary

The main purpose of this study is to assess the safety and efficacy of MK-1167 administered
 to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06285240
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06285240 through Pure Global AI's free database. This Phase 1 trial is sponsored by Merck Sharp & Dohme LLC and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.